Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipegfilgrastim versus filgrastim in pediatric chemotherapy-induced neutropenia
2015-000087-34Phase 2Completed
- Sponsor
- Merckle GmbH
- Start
- Apr 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chemotherapy-induced neutropenia (CIN) comparing Lipegfilgrastim arm with Filgrastim control arm (2 arms). Primary endpoint: Duration of severe neutropenia in cycle 1. Started Apr 2015; status: completed.
02
Drugs
lipegfilgrastimfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2015-000087-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000087-34.